Gulhati Details Treatments and Advances in Pancreatic Cancer

Prateek Gulhati, MD, PhD, delivers takeaways from his presentation at the 2022Annual Oncology Clinical Practice and Research Summit and key trials in pancreatic cancer that have moved the field forward. He cites approvals of FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine/paclitaxel chemotherapy regimens as notable advances of the past decade. However, further research is needed to determine what patients derive benefit from immunotherapies and maintenance PARP inhibitors, Gulhati says, adding that the biggest unmet needs are a technique for early detection of pancreatic cancer and more active therapies, as chemotherapy remains the primary treatment in the metastatic setting.

TO WATCH, VISIT bit. ly/3JdWsXL.